Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Iconic Labs

BST:W0G
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
W0G
BST
£270K
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Iconic Labs Plc provides consulting and agency services. The last earnings update was 152 days ago. More info.


Add to Portfolio Compare Print
W0G Share Price and Events
7 Day Returns
0%
BST:W0G
8.4%
DE Healthcare
9.9%
DE Market
1 Year Returns
-66.7%
BST:W0G
-25.6%
DE Healthcare
-17.5%
DE Market
W0G Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Iconic Labs (W0G) 0% 0% 0% -66.7% -99.6% -
DE Healthcare 8.4% -16.2% -21.1% -25.6% -43.3% -32%
DE Market 9.9% -16.6% -24.8% -17.5% -24.5% -28.1%
1 Year Return vs Industry and Market
  • W0G underperformed the Healthcare industry which returned -25.6% over the past year.
  • W0G underperformed the Market in Germany which returned -17.5% over the past year.
Price Volatility
W0G
Industry
5yr Volatility vs Market

Value

 Is Iconic Labs undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Iconic Labs is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Iconic Labs has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Iconic Labs. This is due to cash flow or dividend data being unavailable. The share price is €0.0005.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Iconic Labs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Iconic Labs's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:W0G PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in GBP £0.00
LSE:ICON Share Price ** LSE (2020-03-05) in GBP £0
Germany Healthcare Industry PE Ratio Median Figure of 9 Publicly-Listed Healthcare Companies 27.51x
Germany Market PE Ratio Median Figure of 399 Publicly-Listed Companies 16.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Iconic Labs.

BST:W0G PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:ICON Share Price ÷ EPS (both in GBP)

= 0 ÷ 0.00

-0.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Iconic Labs is loss making, we can't compare its value to the DE Healthcare industry average.
  • Iconic Labs is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Iconic Labs's expected growth come at a high price?
Raw Data
BST:W0G PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.23x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.22x
Germany Market PEG Ratio Median Figure of 255 Publicly-Listed Companies 1.18x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Iconic Labs, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Iconic Labs's assets?
Raw Data
BST:W0G PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in GBP £0.00
LSE:ICON Share Price * LSE (2020-03-05) in GBP £0
Germany Healthcare Industry PB Ratio Median Figure of 14 Publicly-Listed Healthcare Companies 1.13x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.43x
BST:W0G PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:ICON Share Price ÷ Book Value per Share (both in GBP)

= 0 ÷ 0.00

-0.14x

* Primary Listing of Iconic Labs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Iconic Labs has negative assets, we can't compare the value of its assets to the DE Healthcare industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Iconic Labs's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Healthcare industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Iconic Labs's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Iconic Labs has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Iconic Labs expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Iconic Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.4%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Iconic Labs expected to grow at an attractive rate?
  • Unable to compare Iconic Labs's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Iconic Labs's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Iconic Labs's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:W0G Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 9.4%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:W0G Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:W0G Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-06-30 -3 0
2018-06-30 0 -2 -4
2018-03-31 0 -2 -3
2017-12-31 0 -2 -3
2017-09-30 0 -2 -2
2017-06-30 0 -2 -2
2017-03-31 0 -1 -2
2016-12-31 0 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Iconic Labs is high growth as no earnings estimate data is available.
  • Unable to determine if Iconic Labs is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:W0G Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Iconic Labs Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:W0G Past Financials Data
Date (Data in GBP Millions) EPS *
2019-06-30 0.00
2018-06-30 -0.05
2018-03-31 -0.05
2017-12-31 -0.05
2017-09-30 -0.05
2017-06-30 -0.05
2017-03-31 -0.04
2016-12-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Iconic Labs will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Iconic Labs's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  2. Iconic Labs's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Iconic Labs's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Iconic Labs has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Iconic Labs performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Iconic Labs's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Iconic Labs does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Iconic Labs's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Iconic Labs's 1-year growth to the DE Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
Iconic Labs's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Iconic Labs Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:W0G Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -0.21 0.20
2018-06-30 0.04 -3.96 3.38
2018-03-31 0.05 -3.38 3.08
2017-12-31 0.05 -2.81 2.77
2017-09-30 0.05 -2.36 2.33
2017-06-30 0.05 -1.91 1.88
2017-03-31 0.04 -1.59 1.55
2016-12-31 0.03 -1.27 1.22
2015-12-31 0.05 -0.24 0.30
2014-12-31 0.12 -0.19 0.36
2013-12-31 0.00 -0.09 0.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Iconic Labs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Iconic Labs has efficiently used its assets last year compared to the DE Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Iconic Labs improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Iconic Labs's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Iconic Labs has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Iconic Labs's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Iconic Labs's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Iconic Labs's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Iconic Labs's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Iconic Labs's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Iconic Labs has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Iconic Labs Company Filings, last reported 9 months ago.

BST:W0G Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 -1.67 0.00 0.02
2018-06-30 -0.64 1.17 1.73
2018-03-31 -0.64 1.17 1.73
2017-12-31 -0.57 0.81 0.62
2017-09-30 -0.57 0.81 0.62
2017-06-30 0.57 0.63 0.87
2017-03-31 0.57 0.63 0.87
2016-12-31 0.82 0.23 1.15
2015-12-31 -0.69 0.71 0.03
2014-12-31 -0.22 0.20 0.01
2013-12-31 -0.06 0.00 0.00
  • Iconic Labs has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Iconic Labs's debt level has increased considering it has negative shareholder equity.
  • Iconic Labs has no debt, it does not need to be covered by operating cash flow.
  • Iconic Labs has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Iconic Labs's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Iconic Labs has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Iconic Labs's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Iconic Labs dividends.
If you bought €2,000 of Iconic Labs shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Iconic Labs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Iconic Labs's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:W0G Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.8%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Iconic Labs has not reported any payouts.
  • Unable to verify if Iconic Labs's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Iconic Labs's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Iconic Labs has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Iconic Labs's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Iconic Labs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Iconic Labs has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Iconic Labs's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Quinlan
CEO Bio

Mr. John Quinlan has been is Chief Executive Officer at Iconic Labs Plc and serves as its Executive Director. Mr. Quinlan served as Non-Executive Director since March 18, 2019. He spent four years at UNILAD, where he helped take revenues to over £10 million during this time.

CEO Compensation
  • Insufficient data for John to compare compensation growth.
  • Insufficient data for John to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Peter Hollands

TITLE
Director of WideCells Storage and Research Division & Group's Chief Scientific Officer
COMPENSATION
£102K
AGE
60

João Carlos Martins Gil

TITLE
COMPENSATION
£125K
AGE
58
TENURE
1.7 yrs

Marilyn Orcharton

TITLE
COMPENSATION
£20K
AGE
77
TENURE
1.7 yrs

David G. Sefton

TITLE
Executive Chairman
AGE
48

John Quinlan

TITLE
CEO & Executive Director

Sam Asante

TITLE
COO & Executive Director
AGE
28

Liam Harrington

TITLE
Chief Business Officer & Executive Director
Board of Directors Tenure

Average tenure of the Iconic Labs board of directors in years:

1.6
Average Tenure
  • The average tenure for the Iconic Labs board of directors is less than 3 years, this suggests a new board.
Board of Directors

David G. Sefton

TITLE
Executive Chairman
AGE
48
TENURE
1 yrs

John Quinlan

TITLE
CEO & Executive Director
TENURE
1 yrs

Sam Asante

TITLE
COO & Executive Director
AGE
28
TENURE
0.3 yrs

Liam Harrington

TITLE
Chief Business Officer & Executive Director
TENURE
1 yrs

Tristan Mckay

TITLE
Chairman of Scientific Advisory Committee
TENURE
2.3 yrs

Richard Shaffer

TITLE
Member of Scientific Advisory Committee
TENURE
2.3 yrs

Ahmed Al-Alawi

TITLE
Member of Scientific Advisory Committee
TENURE
2.3 yrs

Niranjan Bhattacharya

TITLE
Member of Scientific Advisory Committee
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Iconic Labs's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Iconic Labs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Iconic Labs Plc provides consulting and agency services. The company offers advisory services to clients on their businesses; and delivers campaigns, as well as provides creative services to its clients. Its activities include monthly insights, content creation and distribution, post campaign analysis, and combining with online media brands. The company was formerly known as WideCells Group PLC and changed its name to Iconic Labs Plc in July 2019. Iconic Labs Plc was founded in 2012 and is based in London, the United Kingdom.

Details
Name: Iconic Labs Plc
W0G
Exchange: BST
Founded: 2012
£306,040
1,637,129,905
Website: http://www.iconiclabs.co.uk
Address: Iconic Labs Plc
27-28 Eastcastle Street,
London,
Greater London, W1W 8DH,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE ICON Ordinary Shares London Stock Exchange GB GBP 27. Jul 2016
BST W0G Ordinary Shares Boerse-Stuttgart DE EUR 27. Jul 2016
Number of employees
Current staff
Staff numbers
15
Iconic Labs employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 22:49
End of day share price update: 2020/03/05 00:00
Last earnings filing: 2019/10/31
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.